Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Lenvatinib
Treatment for Thyroid cancer
Typical Dosage: 24 mg orally once daily
Effectiveness
75%
Safety Score
30%
Clinical Trials
36
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
24 mg orally once daily
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
3(Treat 3 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$4,000
Side Effect Mgmt:$7,000
Total Annual:$211,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$324,615
Cost per Remission
$21,100,000
Comparison vs Sorafenib
Cost Difference
+$10,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Lenvatinib Outcomes
for Thyroid cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Remission Rate
+1%
Common Side Effects
Hypertension
+70%
Fatigue
+67%
Diarrhea
+59%
Nausea
+45%
Decreased appetite
+39%
Weight decrease
+35%
Proteinuria
+32%
Palmar-plantar erythrodysesthesia syndrome (PPE)
+34%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
5 active trials recruiting for Lenvatinib in Thyroid cancer
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
NCT07092514RECRUITINGPHASE2
34 participants
INTERVENTIONAL
St Louis, United States
Started: Oct 14, 2025
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
NCT04171622ACTIVE NOT RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Houston, United States
Started: Nov 4, 2021
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
NCT05696548ACTIVE NOT RECRUITINGPHASE2
51 participants
INTERVENTIONAL
Nagoya, Japan +9 more
Started: Jul 2, 2019
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
NCT06374602RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Saint Petersburg, Russia
Started: Mar 25, 2024
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954ACTIVE NOT RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Mar 9, 2021
Completed Clinical Trials
10 completed trials for Lenvatinib in Thyroid cancer
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
NCT02430714COMPLETED
629 participants
OBSERVATIONAL
Osaka, Japan +1 more
Started: May 20, 2015
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
NCT03573960COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Bangalore, India +10 more
Started: Apr 1, 2018
A Study of E7080 in Subjects With Advanced Thyroid Cancer
NCT01728623COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Kashiwa, Japan +2 more
Started: Sep 3, 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
NCT01321554COMPLETEDPHASE3
392 participants
INTERVENTIONAL
Little Rock, United States +154 more
Started: Mar 17, 2011
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
NCT02702388COMPLETEDPHASE2
241 participants
INTERVENTIONAL
La Jolla, United States +100 more
Started: Jun 8, 2017
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
NCT02432274COMPLETEDPHASE1, PHASE2
117 participants
INTERVENTIONAL
Houston, United States +18 more
Started: Dec 29, 2014
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
NCT02973997COMPLETEDPHASE2
57 participants
INTERVENTIONAL
Torrance, United States +6 more
Started: Feb 7, 2018
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
NCT00784303COMPLETEDPHASE2
117 participants
INTERVENTIONAL
Little Rock, United States +41 more
Started: Nov 6, 2008
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
NCT02726503COMPLETEDPHASE2
39 participants
INTERVENTIONAL
Nagoya, Japan +22 more
Started: Apr 4, 2016
Post-Marketing Surveillance of Lenvima in Korean Patients
NCT02764554COMPLETED
132 participants
OBSERVATIONAL
Anyang, South Korea +31 more
Started: Nov 10, 2016
Showing 20 of 37 total trials